Tevogen Bio Announces Series A-1 Preferred Stock Investment
27 mars 2024 09h20 HE
|
Tevogen Bio Inc
The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.
AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmune
13 mars 2024 07h59 HE
|
AB Science
COMMUNIQUÉ DE PRESSE DE NOUVELLES RECHERCHES MONTRENT QUE LE MASITINIB LIMITE LES DOMMAGES NEURONAUX DANS UN MODÈLE DE MALADIE NEURODÉGÉNÉRATIVE D'ORIGINE NEUROIMMUNE C'EST LA PREMIÈRE FOIS QUE LE...
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
13 mars 2024 07h59 HE
|
AB Science
PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM...
PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Poland
11 mars 2024 02h00 HE
|
PolTREG S.A.
Gdańsk, Poland – 11 March 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces it...
Auto-Injectors Market revenue to surpass USD 33 Billion by 2036, says Research Nester
21 févr. 2024 07h00 HE
|
Research Nester
New York , Feb. 21, 2024 (GLOBE NEWSWIRE) -- The global auto-injectors market size is predicted to expand at 17% CAGR between 2024 and 2036. The market is projected to garner a revenue of USD 33...
PolTREG appoints Dan Shelly as Chief Business Development Officer
21 févr. 2024 01h00 HE
|
PolTREG S.A.
Gdańsk, Poland – 21 February 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune...
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
31 janv. 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat...
PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy
30 janv. 2024 01h00 HE
|
PolTREG S.A.
Gdańsk, Poland – 30 January 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune...
Prefilled Syringes Market revenue to surpass USD 45 Billion by 2033, says Research Nester
25 janv. 2024 05h00 HE
|
Research Nester
New York, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The global prefilled syringes market size is projected to expand at ~13% CAGR between 2023 and 2033.The market is expected to garner a revenue of USD 45...
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
08 janv. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...